FDA approval check
Start with the FDA record
As of September 26, 2026, neither BPC-157 nor retatrutide has an FDA-approved medicine in the US.
As of that date, FDA also stated that federal law does not allow retatrutide in compounded medicines.
Field questions / ask it plainly
Ask the question you came with.
Ask about the medicine, the person treating you and the plan after the visit. If an answer is unclear, ask for it in plain words.
Words used in this note
- Telehealth
- Care through a screen, phone or online exchange.
- Compounding
- Preparing a medicine to meet a patient need.
- Clinical trial
- A research study testing a treatment in people.
Is peptide care real and allowed?
There is no useful yes-or-no answer for every product called a peptide. Food and Drug Administration (FDA) reviews a proposed medicine’s evidence in the US.
As of September 26, 2026, FDA-approved peptide medicines include Ozempic and Wegovy (semaglutide), plus Mounjaro and Zepbound (tirzepatide).
As of October 1, 2026, Alabama’s medical board prohibits clinician involvement in recommending, prescribing or giving patients research-grade peptides.
- Which exact medicine do you mean?
- What health problem would it treat?
- Has FDA approved it, and does Alabama allow you to prescribe it?
Can care begin online, or do I need a clinic visit?
Ask whether the assessment can answer the question you are bringing.
As of October 1, 2026, Alabama permits a doctor-patient relationship to start through telehealth without a prior in-person examination.
The Federation of State Medical Boards offers guidance to state boards; it advises doctors to arrange in-person care when an online visit cannot supply a needed exam or test.
- How will you assess my concern?
- What would make an in-person visit necessary?
- Who arranges that visit if it is needed?
What if the offer names BPC-157 or retatrutide?
An unfamiliar name is a reason to ask for the actual record.
- Ask whether the exact medicine has FDA approval and can legally be prescribed in Alabama.
- Ask how the medicine meets Alabama’s board notice.
- A name from a research study, or a drug identification number, is not proof of FDA approval.
What else is worth asking?
Keep the conversation tied to a decision, not a broad promise.
- What benefit are we looking for, and how will we judge it?
- What problems need prompt attention?
- Which pharmacy prepares or fills the prescription?
- What does the full plan cost after any introductory offer?
- How will follow-up work if the plan is not helping?
- What are the alternatives, including no medicine?
Keep going
Keep the source trail handy